<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Quidelortho Corporation — News on 6ix</title>
<link>https://6ix.com/company/quidel-corporation</link>
<description>Latest news and press releases for Quidelortho Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 05 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/quidel-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b3d578dffbe2df112d8b.webp</url>
<title>Quidelortho Corporation</title>
<link>https://6ix.com/company/quidel-corporation</link>
</image>
<item>
<title>QuidelOrtho Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-reports-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 05 May 2026 20:05:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026.</description>
</item>
<item>
<title>Understanding and Addressing Syphilis Trends - and What's Being Missed</title>
<link>https://6ix.com/company/quidel-corporation/news/understanding-and-addressing-syphilis-trends-and-whats-being-missed</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/understanding-and-addressing-syphilis-trends-and-whats-being-missed</guid>
<pubDate>Thu, 23 Apr 2026 13:32:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving syphilis trends in the United States and the rise of congenital syphilis cases despite declines in early-stage infections.</description>
</item>
<item>
<title>TTP Group Announces the Sale of LEX Diagnostics</title>
<link>https://6ix.com/company/quidel-corporation/news/ttp-group-announces-the-sale-of-lex-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/ttp-group-announces-the-sale-of-lex-diagnostics</guid>
<pubDate>Mon, 20 Apr 2026 11:56:00 GMT</pubDate>
<description>CAMBRIDGE, England, April 20, 2026--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group.</description>
</item>
<item>
<title>QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-corporation-completes-acquisition-of-lex-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-corporation-completes-acquisition-of-lex-diagnostics</guid>
<pubDate>Mon, 20 Apr 2026 11:12:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.</description>
</item>
<item>
<title>QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-announces-preliminary-revenue-for-the-first-quarter-2026-and-provides-update-on-full-year-2026-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-announces-preliminary-revenue-for-the-first-quarter-2026-and-provides-update-on-full-year-2026-guidance</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics,</description>
</item>
<item>
<title>Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer</title>
<link>https://6ix.com/company/quidel-corporation/news/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is</description>
</item>
<item>
<title>Faster Cardiac Answers with High‑Sensitivity Troponin</title>
<link>https://6ix.com/company/quidel-corporation/news/faster-cardiac-answers-with-highsensitivity-troponin</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/faster-cardiac-answers-with-highsensitivity-troponin</guid>
<pubDate>Thu, 19 Feb 2026 14:17:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.</description>
</item>
<item>
<title>QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-to-present-at-the-47th-annual-raymond-james-institutional-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-to-present-at-the-47th-annual-raymond-james-institutional-investor-conference</guid>
<pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference.</description>
</item>
<item>
<title>QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-enters-strategic-supply-agreement-to-expand-global-immunoassay-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-enters-strategic-supply-agreement-to-expand-global-immunoassay-portfolio</guid>
<pubDate>Mon, 16 Feb 2026 06:00:00 GMT</pubDate>
<description>QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States.</description>
</item>
<item>
<title>QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-reports-fourth-quarter-full-210500217</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-reports-fourth-quarter-full-210500217</guid>
<pubDate>Wed, 11 Feb 2026 21:05:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025.</description>
</item>
<item>
<title>QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-receives-excellence-services-label-121200245</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-receives-excellence-services-label-121200245</guid>
<pubDate>Tue, 03 Feb 2026 12:12:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction.</description>
</item>
<item>
<title>Strengthening the blood supply: Awareness, challenges and donor impact</title>
<link>https://6ix.com/company/quidel-corporation/news/strengthening-blood-supply-awareness-challenges-121200733</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/strengthening-blood-supply-awareness-challenges-121200733</guid>
<pubDate>Thu, 22 Jan 2026 12:12:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. With decades of experience in blood banking and immunohematology, Mullens shares insights into the pressures on today's blood supply and the importance of consistent donor engagement.</description>
</item>
<item>
<title>QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-report-fourth-quarter-and-full-year-2025-financial-results-2026-01-21</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-report-fourth-quarter-and-full-year-2025-financial-results-2026-01-21</guid>
<pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics,</description>
</item>
<item>
<title>Neogen® Announces Two Senior Leadership Appointments</title>
<link>https://6ix.com/company/quidel-corporation/news/neogenr-announces-two-senior-leadership-appointments</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/neogenr-announces-two-senior-leadership-appointments</guid>
<pubDate>Mon, 05 Jan 2026 13:45:00 GMT</pubDate>
<description>LANSING, Mich., January 05, 2026--Neogen Corporation (NASDAQ: NEOG) today announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer, effective January 5, 2026, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety, effective January 7, 2026.</description>
</item>
<item>
<title>Innovating Diagnostics and What's Next</title>
<link>https://6ix.com/company/quidel-corporation/news/innovating-diagnostics-and-whats-next</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/innovating-diagnostics-and-whats-next</guid>
<pubDate>Thu, 18 Dec 2025 14:17:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring Jonathan Siegrist, PhD, Executive Vice President of Research & Development and Chief Technology Officer at QuidelOrtho. Dr. Siegrist is a recognized leader in molecular diagnostics and biomedical engineering, driving innovation and next-generation diagnostic solutions.</description>
</item>
<item>
<title>QuidelOrtho To Participate In Upcoming Investor Conferences</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-participate-upcoming-investor-conferences-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-participate-upcoming-investor-conferences-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 24, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that</description>
</item>
<item>
<title>The Power of Prevention: Detecting Diabetes Before It Strikes</title>
<link>https://6ix.com/company/quidel-corporation/news/the-power-of-prevention-detecting-diabetes-before-it-strikes</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/the-power-of-prevention-detecting-diabetes-before-it-strikes</guid>
<pubDate>Thu, 20 Nov 2025 14:00:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics.</description>
</item>
<item>
<title>QuidelOrtho Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-reports-third-quarter-2025-financial-results-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-reports-third-quarter-2025-financial-results-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ―</description>
</item>
<item>
<title>QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay</title>
<link>https://6ix.com/company/quidel-corporation/news/quidelortho-receives-fda-510k-clearance-vitrostm-immunodiagnostic-products-hs</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/quidelortho-receives-fda-510k-clearance-vitrostm-immunodiagnostic-products-hs</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Clearance expands menu and enables high-sensitivity troponin I measurement to aid in the diagnosis of myocardial infarction SAN DIEGO, Nov. 3, 2025</description>
</item>
<item>
<title>Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics</title>
<link>https://6ix.com/company/quidel-corporation/news/informatics-illuminated-science-bytes-podcast-explores-the-power-behind-smarter-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/quidel-corporation/news/informatics-illuminated-science-bytes-podcast-explores-the-power-behind-smarter-diagnostics</guid>
<pubDate>Thu, 23 Oct 2025 22:45:00 GMT</pubDate>
<description>QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring George Wierschem, MBA, MT(ASCP), Senior Global Product Manager – Informatics.</description>
</item>
</channel>
</rss>